History and current standard of postnatal management in hemolytic disease of the fetus and newborn.

Abstract

Multiple developments have improved the identification, monitoring, and care of pregnancies and neonates withHDFN throughout the centuries. Pediatricians should be aware of the (antenatally determined) risk of hemolysis inRBC alloimmunization and should provide treatment for hyperbilirubinemia in the early phase and monitor for lateanemia in the late phase of the disease. Future studies should be set in an international setting and ultimately aimto eradicate HDFN on a global scale. •Developments have led to a greater understanding of the pathophysiology, an improved serological identification and monitoring of at-risk cases and the current pre- and postnatal treatment. •This review provides the pediatrician with hands-on guidelines for the delivery and postnatal management of neonates with HDFN. • Future studies should be set in an international setting with the ultimate aim of eradicating HDFN.